Trevi Therapeutics Highlights RIVER Trial at ERS Congress 2025
Trevi Therapeutics Showcases Groundbreaking Research
Trevi Therapeutics, Inc. (NASDAQ: TRVI), a pioneering clinical-stage biopharmaceutical company, has exciting news to share. They have announced that important findings from their Phase 2a trial, known as the RIVER trial, will be highlighted at the upcoming European Respiratory Society (ERS) Congress 2025. This congress is a significant event in the respiratory community, and it is set to take place in Amsterdam, Netherlands.
Insights from the RIVER Trial
The Phase 2a RIVER trial focuses on exploring the investigational therapy Haduvio™ (oral nalbuphine extended-release), specifically targeting chronic cough related to idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). These conditions can lead to debilitating health issues, making the findings from the trial all the more critical.
Poster Presentations at ERS Congress
During the ERS Congress, Trevi Therapeutics will present two prominent posters detailing the outcomes of the RIVER trial. The data presented will delve into the efficacy and safety of nalbuphine ER, providing attendees with a comprehensive view of its impact on patients suffering from RCC.
Abstract Highlights
The abstracts to be showcased include:
- Efficacy and safety of nalbuphine extended-release in refractory chronic cough: results from the Phase 2a RIVER trial - This presentation will occur during the Poster Session 305, focusing on innovative approaches to cough management.
- Responder analysis of nalbuphine extended-release in refractory chronic cough: results from the RIVER Phase 2a trial - This will be presented in Poster Session 158, concentrating on lung physiology in interstitial lung disease.
The session dates are scheduled for September 29 and September 28, respectively, and will feature critical data pertinent to patient treatment strategies.
The Importance of Addressing Refractory Chronic Cough
RCC is increasingly recognized as a condition that requires urgent attention. Defined as a cough persisting for more than eight weeks despite treatment for underlying issues, it affects approximately 2-3 million people across the United States. The chronic nature of this cough can lead to a range of complications, greatly impacting the quality of life for patients.
Understanding the Challenges of RCC
Many individuals suffering from RCC contend with heightened sensitivity of the cough reflex, which is thought to result from both central and peripheral nervous system involvement. The widespread nature of the condition illustrates the necessity for effective therapies. As there are currently no FDA-approved solutions, Trevi Therapeutics aims to fill this substantial gap with Haduvio, which operates as a kappa agonist and a mu antagonist (KAMA).
About Trevi Therapeutics, Inc.
Founded with a mission to address chronic cough, Trevi Therapeutics has made significant strides in developing Haduvio. Research reveals that Haduvio demonstrates a statistically significant reduction in cough frequency among patients with both IPF chronic cough and RCC. The statistics are compelling; many individuals can cough more than 1,500 times per day, highlighting the need for innovative treatments.
With a pressing need for effective therapies in chronic cough, Trevi Therapeutics intends to propose Haduvio as the trade name for nalbuphine ER, alternatives that are fashioned to assist patients experiencing chronic cough burdens.
Frequently Asked Questions
What is the RIVER trial about?
The RIVER trial assesses nalbuphine ER's safety and efficacy in treating refractory chronic cough, aiming to offer new treatment options for patients.
When will the results be presented?
The results will be presented during the ERS Congress 2025, with sessions scheduled for September 28 and September 29.
What conditions does Haduvio target?
Haduvio aims to address chronic cough due to IPF, non-IPF ILD, and RCC, which are serious health conditions without FDA-approved therapies.
How does RCC affect patients?
RCC can cause significant physical, psychological, and social challenges, leading to a diminished overall quality of life.
Is there an FDA approval for Haduvio?
As of now, Haduvio is still under investigation and has not received FDA approval yet, but its clinical trials show promising results.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.